OBJECTIVES:  This analysis examines the use of antipsychotics among seniors living in long-term care (LTC) facilities, and the concurrent use of antipsychotics with other psychotropic drugs, which further increases risk of side effects. It also looks at the characteristics of residents treated with antipsychotics, including diagnoses, behaviours and other functional measures. METHODS:  Drug claims data from the National Prescription Drug Utilization Information System (NPDUIS) Database, housed at the Canadian Institute for Health Information (CIHI), provide detailed information about antipsychotic use. LTC resident assessment data from CIHI’s Continuing Care Reporting System (CCRS) provide detailed resident information. RESULTS:  Residents with severe cognitive impairment and those exhibiting highly aggressive behaviour were more likely to have used an antipsychotic. However, a large proportion of seniors exhibiting severe aggression were not treated with antipsychotics, suggesting that non-drug alternatives were often considered. Quetiapine was the most commonly used antipsychotic (19.2% of LTC residents), followed by risperidone (14.1%). Among seniors who were chronic users of an antipsychotic, nearly two-thirds (64.3%) were also chronic users of an antidepressant, while roughly 1 in 6 (15.0%) were also chronic users of a benzodiazepine. In Manitoba, antipsychotic use decreased from 38.2% in 2006 to 31.5% in 2014. This was due in part to initiatives implemented by the Winnipeg Regional Health Authority, to reduce inappropriate antipsychotic use in LTC facilities. CONCLUSIONS:  In September 2014, The Canadian Foundation for Healthcare Improvement began supporting several health care organizations across Canada to adopt initiatives to reduce inappropriate antipsychotic use in LTC facilities. As more facilities start implementing similar strategies, the overall rate of antipsychotics use in LTC facilities may decrease.